Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)

NCT06937229 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT06937229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06937229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-3)
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 3
Overall status
Recruiting
Start date
December 2, 2025
Completion date
July 20, 2029
Enrollment
650 (estimated)
Sites
252

Conditions

As the registry lists them; a condition with its own page is linked.

agitation, alzheimer disease